Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 2/20 | 0.58 |
| ▸ | JUN | P05412 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276443 | 0.92 | FOS (0.62) | FOSJUNALDH1A1HIF1AHPGD | |
| SCHEMBL4280879 | 0.90 | FOS (0.62) | FOSJUNALDH1A1HIF1AHPGD | |
| SCHEMBL4278642 | 0.85 | FOS (0.59) | FOSJUNALDH1A1HIF1AHPGD | |
| SCHEMBL2968551 | 0.85 | FOS (0.55) | FOSJUNALDH1A1HIF1AHPGD | |
| SCHEMBL4279592 | 0.84 | FOS (0.54) | FOSJUNALDH1A1HIF1AHPGD | |
| SCHEMBL4277644 | 0.84 | FOS (0.64) | FOSJUNALDH1A1HIF1AHPGD | |
| SCHEMBL2959153 | 0.84 | JUN (0.54) | FOSJUNALDH1A1HIF1AHPGD | |
| SCHEMBL4285838 | 0.83 | JUN (0.52) | FOSJUNALDH1A1HIF1AHPGD | |
| SCHEMBL4291386 | 0.83 | JUN (0.52) | FOSJUNALDH1A1HIF1AHPGD | |
| SCHEMBL4282186 | 0.83 | FOS (0.53) | FOSJUNALDH1A1HIF1AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| CN-101284865-A | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2008-10-15 | — | — | CN | disclosed |
| CN-100378063-C | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2008-04-02 | — | — | CN | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | FOS 63/4885JUN 20/4885ALDH1A1 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.